Efficacy of Delayed Thrombolytic Tenecteplase Intervention in Ischemic Stroke
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 3rd, 2024
|
Administering thrombolytic agents like alteplase within 4.5 hours of an ischemic stroke is currently the standard practice. The American Heart Association recommends using tenecteplase, a type of alteplase, for this purpose. However, the efficacy of thrombolytic agent administration after 4.5 hours from the onset of the disease remains poorly understood. Consequently, a study was conducted to evaluate the impact of delayed intervention.
The trial involved 458 patients, with an average age of approximately 72 years, who exhibited a median score of 12 on the National Institutes of Health Stroke Scale (NIHSS), ranging from 0 to 42. CT angiography and MRI imaging revealed that nearly half of the patients had occlusion in the M1 segment, while around 40% showed occlusion in the M2 segment, and approximately 10% had a blockage in the internal carotid artery. These participants were randomly allocated to receive either tenecteplase at a dose of 0.25 mg per kilogram of body weight or a placebo within 12 hours of symptom onset. Observation at the 90th day indicated no discernible difference in mortality or symptomatic intracranial hemorrhage between the two groups.
The trial involved 458 patients, with an average age of approximately 72 years, who exhibited a median score of 12 on the National Institutes of Health Stroke Scale (NIHSS), ranging from 0 to 42. CT angiography and MRI imaging revealed that nearly half of the patients had occlusion in the M1 segment, while around 40% showed occlusion in the M2 segment, and approximately 10% had a blockage in the internal carotid artery. These participants were randomly allocated to receive either tenecteplase at a dose of 0.25 mg per kilogram of body weight or a placebo within 12 hours of symptom onset. Observation at the 90th day indicated no discernible difference in mortality or symptomatic intracranial hemorrhage between the two groups.